78 related articles for article (PubMed ID: 26802332)
41. High serum cholesterol: a missed risk factor for chronic kidney disease mortality.
Bikbov B; Perico N; Remuzzi G;
Lancet Diabetes Endocrinol; 2014 Aug; 2(8):613-4. PubMed ID: 25182460
[No Abstract] [Full Text] [Related]
42. Serum Bicarbonate and Kidney Disease Progression and Cardiovascular Outcome in Patients With Diabetic Nephropathy: A Post Hoc Analysis of the RENAAL (Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan) Study and IDNT (Irbesartan Diabetic Nephropathy Trial).
Schutte E; Lambers Heerspink HJ; Lutgers HL; Bakker SJ; Vart P; Wolffenbuttel BH; Umanath K; Lewis JB; de Zeeuw D; Gansevoort RT
Am J Kidney Dis; 2015 Sep; 66(3):450-8. PubMed ID: 25987260
[TBL] [Abstract][Full Text] [Related]
43. Relevance of serum sclerostin concentrations in critically ill patients.
Koch A; Weiskirchen R; Ludwig S; Buendgens L; Bruensing J; Yagmur E; Baeck C; Herbers U; Trautwein C; Tacke F
J Crit Care; 2017 Feb; 37():38-44. PubMed ID: 27621111
[TBL] [Abstract][Full Text] [Related]
44. Impact of Lipoprotein(a) on Long-term Outcomes in Patients With Diabetes Mellitus Who Underwent Percutaneous Coronary Intervention.
Konishi H; Miyauchi K; Shitara J; Endo H; Wada H; Doi S; Naito R; Tsuboi S; Ogita M; Dohi T; Kasai T; Okazaki S; Isoda K; Suwa S; Daida H
Am J Cardiol; 2016 Dec; 118(12):1781-1785. PubMed ID: 27712648
[TBL] [Abstract][Full Text] [Related]
45. NTproBNP in insulin-resistance mediated conditions: overweight/obesity, metabolic syndrome and diabetes. The population-based Casale Monferrato Study.
Baldassarre S; Fragapani S; Panero A; Fedele D; Pinach S; Lucchiari M; Vitale AR; Mengozzi G; Gruden G; Bruno G
Cardiovasc Diabetol; 2017 Sep; 16(1):119. PubMed ID: 28946871
[TBL] [Abstract][Full Text] [Related]
46. Relationship between serum magnesium levels and cardiovascular events in chronic kidney disease patients.
Kanbay M; Yilmaz MI; Apetrii M; Saglam M; Yaman H; Unal HU; Gok M; Caglar K; Oguz Y; Yenicesu M; Cetinkaya H; Eyileten T; Acikel C; Vural A; Covic A
Am J Nephrol; 2012; 36(3):228-37. PubMed ID: 22948239
[TBL] [Abstract][Full Text] [Related]
47. Influence of continuous erythropoietin receptor activator on markers of cardiovascular risk in chronic kidney disease patients.
Noce A; Dessì M; Durante O; Manca di Villahermosa S; Canale MP; Di Daniele N
Int J Cardiol; 2013 Sep; 167(6):3070-2. PubMed ID: 23218579
[No Abstract] [Full Text] [Related]
48. T lymphocytes and fractalkine contribute to myocardial ischemia/reperfusion injury in patients.
Boag SE; Das R; Shmeleva EV; Bagnall A; Egred M; Howard N; Bennaceur K; Zaman A; Keavney B; Spyridopoulos I
J Clin Invest; 2015 Aug; 125(8):3063-76. PubMed ID: 26168217
[TBL] [Abstract][Full Text] [Related]
49. The magnitude of obesity and metabolic syndrome among diabetic chronic kidney disease population: A nationwide study.
Kittiskulnam P; Thokanit NS; Katavetin P; Susanthitaphong P; Srisawat N; Praditpornsilpa K; Tungsanga K; Eiam-Ong S
PLoS One; 2018; 13(5):e0196332. PubMed ID: 29742114
[TBL] [Abstract][Full Text] [Related]
50. The role of plasma triglyceride/high-density lipoprotein cholesterol ratio to predict cardiovascular outcomes in chronic kidney disease.
Sonmez A; Yilmaz MI; Saglam M; Unal HU; Gok M; Cetinkaya H; Karaman M; Haymana C; Eyileten T; Oguz Y; Vural A; Rizzo M; Toth PP
Lipids Health Dis; 2015 Apr; 14():29. PubMed ID: 25885289
[TBL] [Abstract][Full Text] [Related]
51. [Changes in coagulographic indices in patients with myocardial infarction and concomitant diabetes and without diabetes during anticoagulant treatment].
Maĭmunkov K; Tsekov M; Delibasheva A
Vrach Delo; 1977 Jan; (1):62-5. PubMed ID: 847950
[No Abstract] [Full Text] [Related]
52. Effects on serum fractalkine by diet and omega-3 fatty acid intervention: relation to clinical outcome.
Laake K; Seljeflot I; Fagerland MW; Njerve IU; Arnesen H; Solheim S
Mediators Inflamm; 2015; 2015():373070. PubMed ID: 25733777
[TBL] [Abstract][Full Text] [Related]
53. Sitagliptin and cardiovascular outcomes in diabetic patients with chronic kidney disease after acute myocardial infarction.
Kawada T
Int J Cardiol; 2016 Nov; 222():1072-1073. PubMed ID: 26427543
[No Abstract] [Full Text] [Related]
54. The story of growth differentiation factor 15: another piece of the puzzle.
Lindahl B
Clin Chem; 2013 Nov; 59(11):1550-2. PubMed ID: 24003064
[No Abstract] [Full Text] [Related]
55. Is lipoprotein-associated phospholipase A₂ correlated with cardiovascular risk in European women?
Hirschler V
Indian J Med Res; 2013 Dec; 138(6):832-3. PubMed ID: 24521623
[No Abstract] [Full Text] [Related]
56. Does vitamin K crack calcification in the Chronic Renal Insufficiency Cohort (CRIC)?
Beulens JWJ; Vervloet M
Am J Clin Nutr; 2022 Mar; 115(3):606-607. PubMed ID: 35134829
[No Abstract] [Full Text] [Related]
57. Metabolic syndrome and diabetes in post-acute myocardial infarction patients.
Sans S
Eur J Prev Cardiol; 2018 May; 25(8):826-829. PubMed ID: 29671614
[No Abstract] [Full Text] [Related]
58. PREVENTION OF MYOCARDIAL INFARCTION.
PARISH JG; HORN DB; THOMPSON M
Br Med J; 1963 Nov; 2(5369):1351-2. PubMed ID: 14065062
[No Abstract] [Full Text] [Related]
59. Association between metabolic syndrome and chronic kidney disease.
Kawada T
Clin Chim Acta; 2018 Mar; 478():44. PubMed ID: 29258743
[No Abstract] [Full Text] [Related]
60. Serum Fractalkines and Cardiovascular Outcomes in the CRIC Study Cohort.
Yang P; Xu G
Am J Kidney Dis; 2016 Feb; 67(2):342. PubMed ID: 26802332
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
